XML 15 R4.htm IDEA: XBRL DOCUMENT v3.23.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Operating expenses:        
License costs $ 0 $ 0 $ 50 $ 0
Research and development 1,579 1,685 3,253 3,467
General and administrative 2,510 6,205 6,102 10,719
Acquisition of Exacis in-process research and development 460 0 460 0
Impairment of in-process research and development 0 5,990 0 5,990
Total operating expenses 4,549 13,880 9,865 20,176
Loss from operations (4,549) (13,880) (9,865) (20,176)
Other income (expense), net:        
Change in fair value of warrant liabilities 191 10,792 146 9,470
Change in fair value of contingent consideration 118 0 118 0
Loss on non-controlling investment (8) (296) (59) (911)
Other expense, net (256) (14) (255) (1,156)
Total other income (expense), net 45 10,482 (50) 7,403
Loss before income taxes (4,504) (3,398) (9,915) (12,773)
Provision for income taxes (4) 0 (9) 0
Net loss (4,508) (3,398) (9,924) (12,773)
Series A preferred stock dividend (8) (8) (8) (8)
Net loss attributable to common stockholders $ (4,516) $ (3,406) $ (9,932) $ (12,781)
Net loss per common share - basic (in dollars per share) $ (0.85) $ (1.16) $ (1.9) $ (4.55)
Net loss per common share - diluted (in dollars per share) $ (0.85) $ (1.16) $ (1.9) $ (4.55)
Weighted average shares outstanding - basic (in shares) 5,303 2,940 5,215 2,811
Weighted average shares outstanding - diluted (in shares) 5,303 2,940 5,215 2,811